News

GSK bids for Human Genome Science
Enlarge image

BusinessUK

GSK bids for Human Genome Science

20.04.2012 - Human Genome Science Inc. rebuffs an unsolicited takeover bid from GlaxoSmithKline.

London – European pharma companies have had no luck with US M&A activities recently. First Roche walked away from its acquisition of gene sequencing specialist Illumina Inc.  Now Human Genome Science Inc. (HGS) has rejected an unsolicited US-$2.59bn bid from GlaxoSmithKline. Great Britain’s largest drugmaker offered US-$13 per share in cash, an 81% premium on HGS’s closing share price on March 18.

In spite of that, the Maryland-based biotech said "does not reflect the value inherent in HGS“ and therefore rebuffed the offer. Goldman, Sachs & Co. and Credit Suisse will now advise it on "strategic alternatives" including a possible sale of the company. Obviously, the door for the deal has not closed yet. According to HGS, Glaxo "has been invited to participate in this process“.

GSK's chief executive, Sir Andrew Witty, said he was disappointed that Human Genome had rejected his offer without discussion. "Having worked together with Human Genome Sciences for nearly 20 years, we believe there is clear strategic and financial logic to this combination for both companies and our respective shareholders – and that now is the appropriate time in the evolution of our relationship for our two companies to combine." GSK’s move has been seen as a bet on the sales prospects of several drugs the companies are developing or marketing together. The results for a clinical trial with a diabetes drug are expected for this summer. Last year, the two companies jointly launched Benlysta, the first new drug for lupus in fifty years. 

http://www.european-biotechnology-news.com/news/news/2012-02/gsk-bids-for-us-biotech-hgs.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products